Moderate to Severe Dry Eye Disease Clinical Trial
Official title:
Clinical Trial to Determine Whether Senofilcon A Lenses Provide Relief of Symptoms and Signs in Patients With Moderate to Severe Dry Eye Disease
A clinical trial using Senofilcon A daily lenses in the treatment of moderate to severe dry eye. This a comparison between signs and symptoms prior to and during treatment.
Status | Recruiting |
Enrollment | 32 |
Est. completion date | December 31, 2020 |
Est. primary completion date | December 31, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Confirmed diagnosis of moderate to severe dry eye associated with either Graft-versus-host disease (GVHD), Sjogren syndrome, idiopathic dry eyes, or minimal limbal cell deficiency - A baseline Schirmer tear test (1) of less than 5 mm at 5 minutes without anesthesia - Have a visual analog score for comfort of 50 or less (scale of 1-100, with 100 meaning perfect ocular comfort and 1 meaning severe ocular pain) - Ability or the resources to insert and remove the study lenses - An OSDI score greater than 42 - A willingness to sign an informed consent Exclusion Criteria: - No dry eyes or mild dry eyes - A baseline Schirmer tear test (1) of greater than 5 mm of wetting at 5 minutes - Dry eye comfort score of greater than 50 on a visual analog scale - Unable to insert or remove the study lenses (or have a family member do so) - Have an OSDI score less than 42 - Has been diagnosed with neurotrophic keratopathy in either eye - Unwilling to enroll in the study, and unwilling to provide signed informed consent to participate in the study |
Country | Name | City | State |
---|---|---|---|
United States | University of Illinois at Chicago | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
University of Illinois at Chicago | Johnson & Johnson Vision Care, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Ocular Surface Disease Index (OSDI) | Patient questionaire | 2 weeks |